Recent Analysts’ Ratings Updates for Merus (MRUS)

Merus (NASDAQ: MRUS) recently received a number of ratings updates from brokerages and research firms:

• 3/10/2025 – Merus had its price target lowered by analysts at Bank of America Co. from $73.00 to $70.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Merus had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
• 2/28/2025 – Merus had its “outperform” rating reaffirmed by analysts at William Blair.
• 2/28/2025 – Merus had its price target lowered by analysts at Needham & Company LLC from $85.00 to $83.00. They now have a “buy” rating on the stock.
• 2/13/2025 – Merus is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $84.00 price target on the stock.
• 2/12/2025 – Merus had its “buy” rating reaffirmed by analysts at Guggenheim.
• 2/7/2025 – Merus is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $91.00 price target on the stock.

Merus Trading Down 3.1 %

MRUS traded down $1.52 on Thursday, hitting $47.64. 666,060 shares of the company’s stock were exchanged, compared to its average volume of 648,892. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61. The stock has a market cap of $3.29 billion, a price-to-earnings ratio of -12.06 and a beta of 1.15. The firm has a 50-day moving average price of $42.71 and a 200-day moving average price of $46.42.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, equities analysts predict that Merus will post -3.85 EPS for the current year.

Institutional Investors Weigh In On Merus

A number of large investors have recently made changes to their positions in MRUS. Polar Asset Management Partners Inc. acquired a new position in Merus during the fourth quarter worth $1,318,000. GF Fund Management CO. LTD. purchased a new position in shares of Merus during the 4th quarter worth $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Merus by 17.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company’s stock valued at $4,152,000 after acquiring an additional 14,544 shares during the last quarter. Woodline Partners LP boosted its position in shares of Merus by 0.3% during the 4th quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company’s stock valued at $49,977,000 after acquiring an additional 3,593 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Merus in the fourth quarter valued at about $817,000. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.